Lymphocytotoxic antibodies in leukemic patients treated with bone marrow transplantation.
Lymphocytotoxic antibodies were studied sequentially in a series of 42 patients with leukemia who received a bone marrow graft. Of these patients, 38% had cytotoxic antibodies before bone marrow transplantation (BMT). After BMT the antibody status changed with time, but 62% of the patients had antibodies at some time after BMT. During the first 10 weeks after BMT, 40% of the patients had antibodies. Thereafter the frequency rose to 50% and remained at that level beyond one year after BMT. In successful grafts the gamma globulins are of donor origin six months after BMT; thus donor B cells are capable of forming lymphocytotoxic antibodies even when the immune system is suppressed by cyclosporine. The antibodies had recognizable HLA specificity in about half the cases before and after BMT. When donor and patient were HLA-identical, HLA specificity did not correspond to donor/recipient antigens. In two cases in which the donor was matched for only one haplotype, antibodies formed by recipient cells, active against donor HLA antigens, were found.
Lawler
S D
SD
Jones
E H
EH
Jackson
S
S
Powles
R L
RL
D000961:Antilymphocyte Serum / Q000096:biosynthesis*; D016026:Bone Marrow Transplantation; D003601:Cytotoxicity Tests, Immunologic; D000939:Epitopes / Q000032:analysis; D005260:Female; D006680:HLA Antigens / Q000032:analysis / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007945:Leukemia, Lymphoid / Q000276:immunology* / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy; D008297:Male
D000961:Antilymphocyte Serum; D000939:Epitopes; D006680:HLA Antigens